Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + pertuzumab with or without toripalimab as neoadjuvant therapy for HER2-positive breast cancer
CTR20232220Phase 2Active
- Sponsor
- RemeGen
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, pertuzumab, toripalimab in breast cancer, sponsored by RemeGen. Started Nov 2023; status: active.
02
Drugs
disitamab vedotinpertuzumabtoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232220.